Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-5108 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TD-5108 | DRUG | - |
Inclusion Criteria: * Meet ROME III Criteria Exclusion Criteria: * Constipation caused by:colonic etiology, pelvic floor dysfunction, metabolic disturbances, neurologic disturbances,concomitant medications affecting bowel function * Chronic treatment with anticholinergics, narcotic analgesics * I...
TD-5108 is an investigational small molecule being developed for the treatment of chronic constipation. It is a 5-HT4 agonist, a class of drugs that stimulate serotonin receptors in the gut to promote bowel motility. The drug is currently in Phase 2 clinical development.
TD-5108 is being developed by Theravance Biopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TBPH. The company is conducting clinical trials to evaluate the safety and efficacy of TD-5108 in patients with chronic constipation.
TD-5108 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. One Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
TD-5108 has been studied in one completed Phase 2 clinical trial, identified as NCT00391820, also known as the ACCORD Trial. This randomized, double-blind study enrolled 360 participants with chronic constipation in the United States and evaluated the safety and efficacy of the 5-HT4 agonist.
TD-5108 works as a 5-HT4 agonist, meaning it activates serotonin 5-HT4 receptors in the gastrointestinal tract. This activation enhances bowel motility and secretion, which can help relieve symptoms of chronic constipation. The drug is designed to target these receptors to improve gut function.
TD-5108 is a specific 5-HT4 agonist developed by Theravance Biopharma. While it belongs to the same drug class as other 5-HT4 agonists, it is a distinct investigational compound. No alternative names for TD-5108 have been disclosed in the clinical trial data.